Burke P J, Karp J E, Vaughan W P
J Natl Cancer Inst. 1981 Sep;67(3):529-38.
Studies were conducted in the leukemic mouse and rat to test the hypothesis that enhanced effects of drugs given in sequence relate to a predictable increase in tumor growth and sensitivity to cycle-active agents. The rationale is based on a) evidence that, following drug-induced aplasia, resultant bone marrow proliferation in vivo corresponds temporally with induced humoral stimulatory activity, and on b) models that demonstrate increased cytotoxicity of beta-cytosine arabinoside (Ara-C) to myeloblasts cultured in humoral stimulatory activity (HSA). CD2F1 mice bearing L-1210 leukemia received a course of 60 mg Ara-C/kg every 8th hour (q.8 h) three times on day 0 and on another day in sequence (0,1 through 0,7). The longest survival (250% of controls) was in animals whose second course began on day 3, the time of peak HSA as measured by DNA synthesis induced in L-1210 cells in culture. LBN rats bearing acute myelocytic leukemia (AML) were treated with 100 mg Ara-C/kg q.8 h six times beginning on day 0 and on other days in sequence (0,1 through 0,12). The longest survival was in those treated on day 0,6 (760% of controls), the time of peak serum stimulation, and tumor labeling index (LI). Thirty-seven patients with AML received a single course of therapy with 45 mg Ara-C/kg by a 72-hour infusion and 1.0 mg daunorubicin/kg every day three times. On day 8, the time of peak HSA and tumor LI, Ara-C was again infused. Complete remission was achieved in 56% (65% of all patients less than 60 yr old) with a single cycle of therapy. Median duration of chemotherapy-free remission was 10 months. Of 11 relapsing patients, 8 achieved a second remission with the same regimen. These studies demonstrated that the amount of proliferation of residual tumor and thereby sensitivity to cycle-active drugs given in sequence relates to the initial drug effect on tumor proliferation and the induction of humoral stimulation.
在白血病小鼠和大鼠身上进行了研究,以检验以下假设:序贯给药的增强效果与肿瘤生长的可预测增加以及对细胞周期活性药物的敏感性有关。其基本原理基于:a)有证据表明,在药物诱导的再生障碍之后,体内产生的骨髓增殖在时间上与诱导的体液刺激活性相对应;b)有模型表明,β-阿糖胞苷(Ara-C)对在体液刺激活性(HSA)中培养的成髓细胞的细胞毒性增加。携带L-1210白血病的CD2F1小鼠在第0天和另一天按顺序(0, 1至0, 7)每8小时(q.8 h)接受一次60 mg Ara-C/kg的疗程,共三次。存活时间最长(为对照组的250%)的是那些第二个疗程在第3天开始的动物,第3天是通过培养的L-1210细胞中诱导的DNA合成测量的HSA峰值时间。携带急性髓细胞白血病(AML)的LBN大鼠从第0天开始按顺序(0, 1至0, 12)每8小时接受一次100 mg Ara-C/kg的治疗,共六次。存活时间最长的是那些在第0, 6天接受治疗的大鼠(为对照组的760%),第0, 6天是血清刺激峰值和肿瘤标记指数(LI)的时间。37例AML患者接受了一个疗程的治疗,通过72小时输注给予45 mg Ara-C/kg,每天一次给予1.0 mg柔红霉素/kg,共三次。在第8天,即HSA和肿瘤LI峰值时间,再次输注Ara-C。单周期治疗使56%(所有年龄小于60岁患者的65%)实现了完全缓解。无化疗缓解的中位持续时间为10个月。在11例复发患者中,8例通过相同方案实现了第二次缓解。这些研究表明,残留肿瘤的增殖量以及因此对序贯给予的细胞周期活性药物的敏感性与初始药物对肿瘤增殖的作用以及体液刺激的诱导有关。